false
0002019505
NV
0002019505
2026-03-25
2026-03-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
March 25, 2026
Date of Report (Date of earliest event reported)
Health In Tech, Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
|
001-42449 |
|
87-3545722 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
701 S. Colorado Ave, Suite 1
Stuart, FL |
|
34994 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (888) 373-0333
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Class A Common Stock, $0.001 par value per share |
|
HIT |
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On March 25, 2026, Health
In Tech, Inc., a Nevada corporation (the “Company”), issued a press release announcing its results of operations for the quarter
and year ended December 31, 2025, attached hereto as Exhibit 99.1.
Item 7.01. Regulation FD Disclosure.
As disclosed in Item 2.02
above, on March 25, 2026, the Company issued a press release announcing its results of operations for the quarter and year ended December
31, 2025, attached hereto as Exhibit 99.1. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached
Exhibit 99.1 are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.
The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated
by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation
language in such filing.
Forward-Looking Statements
Certain statements in this
Current Report on Form 8-K are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible
or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry
environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,”
“will,” “should,” “design,” “target,” “aim,” “hope,” “expect,”
“could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,”
“continue,” “predict,” “project,” “potential,” “goal,” or other words that
convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial
performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results,
levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which
could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although
not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in its
forward-looking statements are set forth in the “Risk Factors” section in the Company’s Annual Report on Form 10-K,
its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties
and other important factors may be updated from time to time in the Company’s subsequent reports. Any forward-looking statement
reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and
assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity. Health In Tech undertakes
no obligation to update any forward-looking statements, except as required by law.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
| Exhibit No. |
|
Description |
| 99.1 |
|
Press release dated March 25, 2026. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 25, 2026
HEALTH IN TECH, INC.
| By: |
/s/ Tim Johnson |
|
| Name: |
Tim Johnson |
|
| Title: |
Chief Executive Officer |
|
2
Exhibit 99.1
Health In Tech Announces Fourth Quarter and
Full Year 2025 Financial Results
| ● | Full
year 2025 Revenues of $33.3 million, up 71% YoY |
| ● | Full
year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY |
Stuart, FL., March 25, 2026 /PRNewswire/ —
Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or “Company”), an AI-enabled InsurTech platform company,
today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Financial Highlights for the Full Year 2025
and Fourth Quarter of 2025:
| ● | Revenues. Full
year 2025 revenues were $33.3 million, up 71% year over year (“YoY”). Q4 revenues were $7.5 million, up 53% YoY. |
| ● | Adjusted
EBITDA. Full year 2025 Adjusted EBITDA was $4.1 million, up 81% YoY, Q4 Adjusted EBITDA of $0.3 million compared to prior year Q4
Adjusted EBITDA of $0.5 million. |
| ● | Net
Income. Full year 2025 net income was $1.3 million, up 91% YoY, Q4 net loss of $0.3 million compared to prior year Q4 net loss of
$0.1 million. |
| ● | Billed Enrolled Employees. The number
of billed enrolled employees (EEs) was 22,515 as of December 31, 2025, up 23% YoY. |
| ● | Distribution. The
number of Brokers, Third-party Administrator ("TPAs") and Agencies expanded to 858 partners as of December 31, 2025, up
34% YoY. |
| ● | Cash. Cash
balance was $7.7 million as of December 31, 2025. |
Revenue Outlook
Health In Tech expects full-year 2026 revenue
to be in the range of $45 million to $50 million, representing year-over-year growth of approximately 35% to 50%. This outlook is based
on management’s current expectations and assumptions, including continued strong demand for the Company’s AI-enabled underwriting
marketplace across the self-funded health insurance segment and successful deployment of new features. Actual results may differ materially
due to risks and uncertainties described in Health In Tech’s filings with the SEC.
The Company expects continued growth driven by expanding
engagement across its distribution network and the full deployment of new features launched in January 2026. Unlike the traditional insurance
industry, where new product and service implementations typically require one to two years, Health In Tech’s AI-driven platform
enables new capabilities to be developed and deployed within approximately one to two quarters. This accelerated development cycle provides
a meaningful competitive advantage, allowing the Company to respond quickly to broker and client demand, continuously enhance its marketplace
offerings, and scale its technology platform more efficiently than traditional market participants.
CEO Commentary
Tim Johnson, Chief Executive Officer of
Health In Tech, commented, “2025 was a defining year of disciplined execution and measurable platform scale for
Health In Tech. We strengthened our AI-enabled underwriting marketplace, expanded carrier, broker, and TPA integrations, and further
automated core insurance workflows to drive efficiency and margin scalability. We extended underwriting capabilities into larger
employer segments and continued enhancing our technology architecture to support enterprise-level throughput across the
approximately $300 billion U.S. claims administration market. Most importantly, we translated operational progress into financial
performance, delivering 71% year-over-year revenue growth.”
Mr. Johnson continued, “As we enter 2026, our
focus is on advancing a fully integrated marketplace model that expands beyond underwriting to include additional services such as claims
administration and administrative cost-containment solutions. Building on years of assembling specialized healthcare vendors and service
providers essential to self-funded plans, we enhanced our platform in January 2026 to offer more than 100 pre-configured, customized stop-loss
programs tailored at the broker-agency level. This structured program architecture enables agencies to align standardized offerings with
target employer segments, empowering brokers to deliver execution-ready solutions with greater speed, consistency, and operational efficiency.
The result is shorter sales cycles, improved conversion visibility, and scalable distribution leverage, while maintaining the flexibility
to customize for employer-specific needs.
“In the first half of 2026, we expect to
complete market testing of our Three-Year Rate stabilization program, designed to provide cost stability and predictability for eligible
employer groups. We also plan to initiate beta testing of a new data-driven solution that integrates physiological data and claims data
to generate actionable value insights. Together, these initiatives reflect our strategy of layering incremental, high-value services onto
an already commercialized and scalable platform to drive durable growth and increasing operating leverage.”
Key Developments in Q1 2026
| ● | Engaged
Amazon Web Services (AWS) Advanced Tier Services Partner Ciklum to accelerate development of Health In Tech’s AI-Driven InsurTech
platform. |
| ● | Appointed
former SAP and IBM executive Sri Rajagopalan as Chief Technology Officer to advance AI-driven Enterprise-Grade platform growth. |
| ● | Appointed
five-time founder Zain Hasan as Chief Growth Officer to accelerate revenue growth and scale distribution. |
| ● | Introduced
100+ pre-configured stop-loss self-funded healthcare plans for employers, streamlining the renewal process and reducing cycle times. |
| ● | Hosted
the inaugural independent hitDavos InsurTech Summit during World Economic Forum Week 2026, driving brand visibility and global leadership
engagement across the government, technology, healthcare, and finance sectors. |
Conference Call Details
Health In Tech will host a conference call to
discuss the financial results for the fourth quarter and full year of 2025 on March 25, 2026, at 5:00 p.m. (ET). To participate in our
live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).
A
live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/.
A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and
will remain available for approximately 90 days.
Non-GAAP Financial Information
This release presents Adjusted EBITDA, a non-GAAP
financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted
in the United States of America (“GAAP”). Management uses Adjusted EBITDA to provide investors with additional insight into
operational performance and to facilitate comparison with other companies in the industry. Adjusted EBITDA should not be considered an
alternative to net income, operating income, or other GAAP measures. A reconciliation of historical non-GAAP financial information to
the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.
Use of Forward-Looking Statements
Certain statements in this press release are forward-looking
statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition,
business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In
some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design,"
"target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate,"
"estimate," "believe," "continue," "predict," "project," "potential," "goal,"
or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's
future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual
results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements
because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control
and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement
reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions
relating to Health In Tech's operations, results of operations, growth strategy and liquidity.
About Health In Tech
Health In Tech, Inc. (Nasdaq: "HIT")
is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through
vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales
and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs) and third-party administrators (“TPAs”).
Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for
employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims
administration and reporting integration. Learn more at healthintech.com.
Health In Tech, Inc.
Consolidated Statements of Operations
| | |
Three Months Ended
December 31, | | |
Fiscal
Year Ended
December 31, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Revenues | |
| | |
| | |
| | |
| |
| Revenues from underwriting modeling (ICE) | |
$ | 1,032,381 | | |
$ | 1,697,080 | | |
$ | 6,864,545 | | |
$ | 6,649,271 | |
| Revenues from fees | |
| 6,476,204 | | |
| 3,207,484 | | |
| 26,462,966 | | |
| 12,841,635 | |
| SMR | |
| 6,476,204 | | |
| 2,470,284 | | |
| 26,462,966 | | |
| 9,849,300 | |
| HI Card | |
| - | | |
| 737,200 | | |
| - | | |
| 2,992,335 | |
| Total revenues | |
| 7,508,585 | | |
| 4,904,564 | | |
| 33,327,511 | | |
| 19,490,906 | |
| Cost of revenues | |
| 3,379,942 | | |
| 1,107,173 | | |
| 12,389,783 | | |
| 4,051,439 | |
| Gross profit | |
| 4,128,643 | | |
| 3,797,391 | | |
| 20,937,728 | | |
| 15,439,467 | |
| Operating expenses | |
| | | |
| | | |
| | | |
| | |
| Sales and marketing expenses | |
| 906,206 | | |
| 632,060 | | |
| 4,185,766 | | |
| 3,158,257 | |
| General and administrative expenses | |
| 3,180,137 | | |
| 2,848,014 | | |
| 13,654,262 | | |
| 8,477,407 | |
| Research and development expenses | |
| 213,113 | | |
| 633,653 | | |
| 1,569,262 | | |
| 2,813,899 | |
| Total operating expenses | |
| 4,299,456 | | |
| 4,113,727 | | |
| 19,409,290 | | |
| 14,449,563 | |
| Other income (expense): | |
| | | |
| | | |
| | | |
| | |
| Interest income | |
| 104,659 | | |
| 28,774 | | |
| 409,922 | | |
| 122,885 | |
| Interest expenses | |
| - | | |
| - | | |
| - | | |
| (495,000 | ) |
| Other income | |
| - | | |
| 114,055 | | |
| 118,399 | | |
| 271,211 | |
| Other expense | |
| (377,587 | ) | |
| 62,759 | | |
| (382,587 | ) | |
| - | |
| Total other income (expense), net | |
| (272,928 | ) | |
| 205,588 | | |
| 145,734 | | |
| (100,904 | ) |
| Income (loss) before income tax expense | |
$ | (443,741 | ) | |
$ | (110,748 | ) | |
$ | 1,674,172 | | |
$ | 889,000 | |
| Provision for income taxes | |
| 141,184 | | |
| (33,404 | ) | |
| (395,330 | ) | |
| (218,523 | ) |
| Net income (loss) | |
$ | (302,557 | ) | |
$ | (144,152 | ) | |
$ | 1,278,842 | | |
$ | 670,477 | |
| Net income per share | |
| | | |
| | | |
| | | |
| | |
| Basic | |
$ | (0.01 | ) | |
$ | (0.00 | ) | |
$ | 0.02 | | |
$ | 0.01 | |
| Diluted | |
$ | (0.01 | ) | |
$ | (0.00 | ) | |
$ | 0.02 | | |
$ | 0.01 | |
| Weighted average common stocks outstanding | |
| | | |
| | | |
| | | |
| | |
| Basic | |
| 56,908,999 | | |
| 52,047,723 | | |
| 55,843,821 | | |
| 51,839,329 | |
| Diluted | |
| 58,635,562 | | |
| 54,662,931 | | |
| 57,742,798 | | |
| 53,662,677 | |
Health In Tech, Inc.
Consolidated Balance Sheets
| | |
December 31,
2025 | | |
December 31,
2024 | |
| Assets | |
| | |
| |
| Current assets | |
| | |
| |
| Cash and cash equivalents | |
$ | 7,669,754 | | |
$ | 7,849,248 | |
| Accounts receivable, net | |
| 756,288 | | |
| 1,647,103 | |
| Loans receivable, net | |
| 815,995 | | |
| - | |
| Other receivables, net | |
| 3,467,814 | | |
| 500,252 | |
| Deferred offering costs | |
| 170,977 | | |
| - | |
| Prepaid expenses and other current assets | |
| 3,280,148 | | |
| 787,161 | |
| Total current assets | |
| 16,160,976 | | |
| 10,783,764 | |
| Non-current assets | |
| | | |
| | |
| Software | |
| 6,530,894 | | |
| 3,962,461 | |
| Loans receivable, net | |
| - | | |
| 815,995 | |
| Operating lease - right of use assets | |
| 139,940 | | |
| 206,269 | |
| Long-term prepaid expenses | |
| 258,151 | | |
| - | |
| Total non-current assets | |
| 6,928,985 | | |
| 4,984,725 | |
| Total assets | |
$ | 23,089,961 | | |
$ | 15,768,489 | |
| Liabilities and stockholders' equity | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable and accrued expenses | |
$ | 4,188,811 | | |
$ | 1,858,840 | |
| Income taxes payable | |
| - | | |
| 205,253 | |
| Operating lease liabilities - current | |
| 76,195 | | |
| 66,881 | |
| Other current liability | |
| 891,598 | | |
| - | |
| Total current liabilities | |
| 5,156,604 | | |
| 2,130,974 | |
| Non-current liabilities | |
| | | |
| | |
| Deferred tax liabilities | |
| 757,675 | | |
| 328,676 | |
| Operating lease liabilities - non-current | |
| 63,617 | | |
| 139,811 | |
| Total non-current liabilities | |
| 821,292 | | |
| 468,487 | |
| Total liabilities | |
| 5,977,896 | | |
| 2,599,461 | |
| Stockholders' equity | |
| | | |
| | |
| Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized 46,006,000 and 42,914,870 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | |
| 46,006 | | |
| 42,915 | |
| Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | |
| 11,700 | | |
| 11,700 | |
| Additional paid-in capital | |
| 11,834,121 | | |
| 9,173,017 | |
| Retained earnings | |
| 5,220,238 | | |
| 3,941,396 | |
| Total stockholders' equity | |
| 17,112,065 | | |
| 13,169,028 | |
| Total liabilities and stockholders' equity | |
$ | 23,089,961 | | |
$ | 15,768,489 | |
Health In Tech, Inc.
Consolidated Statements of Cash Flows
| | |
Fiscal Year Ended
December 31, | |
| | |
2025 | | |
2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
| Net income | |
$ | 1,278,842 | | |
$ | 670,477 | |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |
| | | |
| | |
| Bad debt expense (recovery) | |
| (16,234 | ) | |
| 1,878 | |
| Amortization expense | |
| 900,577 | | |
| 541,141 | |
| Provision for refund liability | |
| 3,891,598 | | |
| - | |
| Provision for credit losses on other receivables | |
| 377,587 | | |
| - | |
| Deferred tax expenses (benefits) | |
| 428,999 | | |
| (93,304 | ) |
| Amortization of debt discount | |
| - | | |
| 495,000 | |
| Interest income | |
| (64,000 | ) | |
| (63,996 | ) |
| Stock-based compensation expense | |
| 1,570,419 | | |
| 468,489 | |
| Changes in operating assets and liabilities: | |
| | | |
| | |
| Accounts receivable | |
| 907,049 | | |
| 586,685 | |
| Other receivables | |
| (3,345,149 | ) | |
| 1,180,848 | |
| Prepaid expenses and other assets | |
| (1,948,184 | ) | |
| (514,242 | ) |
| Operating lease right of use assets and liabilities, net | |
| (551 | ) | |
| 1,889 | |
| Accounts payable and accrued expenses | |
| 2,358,113 | | |
| (851,963 | ) |
| Income taxes payable | |
| (205,253 | ) | |
| (246,693 | ) |
| Other current liabilities | |
| (3,000,000 | ) | |
| - | |
| Net cash provided by operating activities | |
| 3,133,813 | | |
| 2,176,209 | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
| Development of software | |
| (3,189,921 | ) | |
| (900,755 | ) |
| Interest received from loans receivable | |
| 64,000 | | |
| 64,000 | |
| Net cash used in investing activities | |
| (3,125,921 | ) | |
| (836,755 | ) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | |
| - | | |
| 8,214,000 | |
| Proceeds from stock option exercises | |
| 23,430 | | |
| - | |
| Payments of deferred offering costs | |
| (210,816 | ) | |
| (1,975,556 | ) |
| Repayments of notes payable | |
| - | | |
| (2,145,000 | ) |
| Net cash provided by (used in) financing activities | |
| (187,386 | ) | |
| 4,093,444 | |
| Increase (decrease) in cash and cash equivalents | |
| (179,494 | ) | |
| 5,432,898 | |
| Cash and cash equivalents, beginning of year | |
| 7,849,248 | | |
| 2,416,350 | |
| Cash and cash equivalents, end of year | |
| 7,669,754 | | |
| 7,849,248 | |
| Supplemental disclosures of cash flow information: | |
| | | |
| | |
| Cash paid for interest | |
$ | - | | |
$ | - | |
| Cash paid for income taxes | |
$ | 830,726 | | |
$ | 558,521 | |
| Summary of noncash investing and financing activities: | |
| | | |
| | |
| Accrued deferred offering costs included in accounts payable and accrued expenses | |
$ | - | | |
$ | 39,839 | |
| Accrued development of software included in accounts payable and accrued expenses | |
$ | 38,363 | | |
$ | 50,000 | |
| Reclassification of deferred offering costs to additional paid-in capital upon initial public offering | |
$ | - | | |
$ | 2,277,164 | |
| Stock-based compensation capitalized for software development | |
$ | 290,726 | | |
$ | - | |
Health In Tech, Inc.
Reconciliation of GAAP (Net Income) to Non-GAAP
Financial Measure (Adjusted EBITDA)
| | |
Three Months Ended
December 31, | | |
Fiscal Year Ended
December 31, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Net income | |
| (302,557 | ) | |
| (144,152 | ) | |
| 1,278,842 | | |
| 670,477 | |
| Interest (income) expenses | |
| (104,659 | ) | |
| (28,774 | ) | |
| (409,922 | ) | |
| 372,115 | |
| Amortization expense | |
| 410,630 | | |
| 135,983 | | |
| 900,577 | | |
| 541,141 | |
| Income tax expense | |
| (141,184 | ) | |
| 33,404 | | |
| 395,330 | | |
| 218,523 | |
| Stock-based compensation expense | |
| 76,733 | | |
| 468,489 | | |
| 1,570,419 | | |
| 468,489 | |
| Provision for credit losses on other receivables | |
| 377,587 | | |
| - | | |
| 377,587 | | |
| - | |
| Total net adjustments | |
| 619,107 | | |
| 609,102 | | |
| 2,833,991 | | |
| 1,600,268 | |
| | |
| | | |
| | | |
| | | |
| | |
| Adjusted EBITDA | |
| 316,550 | | |
| 464,950 | | |
| 4,112,833 | | |
| 2,270,745 | |
Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
dsullivan@theequitygroup.com
7
